Matrix metalloproteinase inhibitor
A matrix metalloproteinase inhibitor (MMPI) inhibits matrix metalloproteinases. As they inhibit cell migration they have antiangiogenic effects. They may be both endogenous and exogenous.
The most notorious endogenous metalloproteinases are tissue inhibitors of metalloproteinases (TIMPs). There are also cartilage-derived angiogenesis inhibitors.
Exogenous matrix metalloproteinase inhibitors were developed as anticancer drugs.[1] Examples include:
- Batimastat
- Cipemastat
- Ilomastat
- Marimastat
- MMI270
- Prinomastat
- Rebimastat
- Ro 28-2653
- Tanomastat
Metalloproteinase inhibitors are found in numerous marine organisms, including fish, cephalopods, mollusks, algae, and bacteria.[2]
References
- Coussens, L. M. (2002). "Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations". Science. 295 (5564): 2387–2392. doi:10.1126/science.1067100. ISSN 0036-8075. PMID 11923519.
- Noel Vinay Thomas; Se Kwon Kim (2010). "Metalloproteinase Inhibitors Stts and Scope from Marine Organisms". Biochemistry Research International. 2010: 845975. doi:10.1155/2010/845975. PMC 3004377. PMID 21197102.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.